China Atorvastatin & Trastuzumab Market with 2018 Forecasts in New Research Reports at ChinaMarketResearchReports.com

ChinaMarketResearchReports.com adds Latest Reports on Atorvastatin and Trastuzumab industry for China to its store.

  • Share on TwitterShare on FacebookShare on Google+Share on LinkedInEmail a friend

Dallas, TX (PRWEB) February 16, 2014

The prevalence rate of abnormal blood lipid in China is lower than that in most developed countries, but the average serum TC level of Chinese people is upgrading for the economic development and lifestyle change. Meanwhile, diabetes and metabolic syndromes are very common in China.

According to statistics, the prevalence rate of abnormal blood lipid is above 20% in the group aged at 18 or above. The total number of patients exceeds 200 million.

Blood lipid-lowering drugs perform better than the overall drug market and cardiovascular system drugs. The expanding rate of blood lipid-lowering drugs is obviously higher than that of cardiovascular system drugs and the proportion in the cardiovascular system drug market is increasing.

Atorvastatin, marketed by Pfizer as a calcium salt under the trade name Lipitor, is a member of the drug class known as statins, used for lowering blood cholesterol. It works by inhibiting HMG-CoA reductase. In November 2011, Pfizer lost the patent protection in the USA. In May 2012, Pfizer lost the patent protection in the U.K. either. Liptor is the most popular drug of Pfizer with the accumulated sales value over USD 100 billion. It is the first drug with sales value breaking USD 100 billion in the history.

Complete report on Atorvastatin Market available @ http://www.chinamarketresearchreports.com/114714.html.

There are many enterprises producing APIs and finished products of atorvastatin. The market share of finished products is mainly occupied by Pfizer, which is above 80% by sales value every year. According to CRI’s investigation, the CAGR of atorvastatin in China sample hospital market is above 40% during 2005-2013.

Trastuzumab is a monoclonal antibody that interferes with the HER2/neu receptor. Its main use is to treat certain breast cancers. Trastuzumab has a major impact in the treatment of HER2-positive metastatic breast cancers.

In China, less than 10% of women can get mammary diseases inspection every year for the limitation of medical conditions and lack of knowledge. Therefore, only 20% of breast cancers is detected at an early stage in China while 80% is detected at an early stage in the U.S.A.

The incidence of breast cancers ranks the first in malignant tumors. According to incomplete statistics, the incidence number of breast cancers exceeds 200,000 every year in China. By the end of 2013, the number of living breast cancer patients exceeded 500,000, above 1/3 of which were metastatic breast cancers. The incidence and mortality rates of breast cancers differ from urban to rural areas in China. In recent 10 years, the incidence of breast cancers in cities obviously increases but the mortality rate remains stable. However, the incidence and mortality rates of breast cancers in rural areas present obvious uprising trend. The number of breast cancer patients in cities is increasing, especially in young women groups. It is mainly caused by the change of lifestyle and diet habits and the incidence growth of other mammary diseases like fibroma. Take Fujian as an instance, from 1970s to the early 21 century, the mortality rate of breast cancers in Fujian presents an upward trend. The mortality rates in 1973-1975, 1990-1992 and 2004-2005 are separately 31.6/million, 34.2/million and 44.6/million. In 2011, the mortality rate of women breast cancer patients was 70.7/million in Fujian. Obviously, the mortality rate doubled during 2005-2011.

In China sample hospital market, the market share of trastuzumab is completely taken by Shanghai Roche and GENENTECH. During 2005-2013, the CAGR of market size of trastuzumab in sample hospitals exceeded 60%. The unit retail price maintains CNY 20,000 (USD 3,300) or more.

The patent of trastuzumab will expire in 2014. The huge profit margin and market potential attract many generic drug manufacturers. CRI sees many generic drugs will enter global market after 2015. According to CRI’s investigation, many generic drug companies add trastuzumab to the R&D list, some of which has certain achievements.

Complete report on Trastuzumab Market available @ http://www.chinamarketresearchreports.com/114713.html.

Browse more reports on Life Sciences Market @ http://www.chinamarketresearchreports.com/cat/life-sciences.html.

Contact sales(at)chinamarketresearch(dot)com for further information.

About Us:
ChinaMarketResearchReports.com (http://www.chinamarketresearchreports.com/) is an online database of market research reports offers in-depth analysis of over 5000 market segments. The library has syndicated reports by leading market research publishers across the globe and also offer customized market research reports for multiple industries.


Contact

Follow us on: Contact's Google Plus